Innate Pharma (IPHA) Other Non-Current Liabilities (2017 - 2025)
Innate Pharma's (IPHA) quarterly Other Non-Current Liabilities came in at $386462.4 in Q4 2025, up 31.99% YoY from $292795.1 in Q4 2024, and down 69.13% on a QoQ basis from $1.3 million in Q2 2025.
Innate Pharma (IPHA) Other Non-Current Liabilities (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Other Non-Current Liabilities data on file, last reported at $386462.4 in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 31.99% year-over-year to $386462.4 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $386462.4 (up 31.99% YoY) and the FY2025 annual result came in at $386462.4, up 31.99% from the prior year.
- Other Non-Current Liabilities eased to $386462.4 in Q4 2025, from $1.3 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $6.8 million in Q2 2021 to a low of $202009.0 in Q4 2022.
- A 5-year average of $1.3 million and a median of $526312.3 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities plunged 97.42% — and 2023, when it surged 221.17%.
- Tracing IPHA's Other Non-Current Liabilities over 5 years: stood at $289424.7 in 2021, then slumped by 30.2% to $202009.0 in 2022, then surged by 221.17% to $648791.8 in 2023, then sank by 54.87% to $292795.1 in 2024, then soared by 31.99% to $386462.4 in 2025.
- The last three Other Non-Current Liabilities figures came in at $386462.4 (Q4 2025), $1.3 million (Q2 2025), and $292795.1 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 386,462.45 |
| Jun 30, 2025 | 1.25 Mn |
| Dec 31, 2024 | 292,795.14 |
| Jun 30, 2024 | 403,832.84 |
| Dec 31, 2023 | 648,791.77 |
| Jun 30, 2023 | 1.91 Mn |
| Dec 31, 2022 | 202,008.98 |
| Jun 30, 2022 | 834,438.33 |
| Dec 31, 2021 | 289,424.65 |
| Jun 30, 2021 | 6.77 Mn |
| Dec 31, 2020 | 263,496.06 |
| Jun 30, 2020 | 262.00 Mn |
| Dec 31, 2019 | 157,178.05 |
| Dec 31, 2018 | 100,442.89 |
| Dec 31, 2017 | 1.19 Mn |